US Tariff and Policy Uncertainty
Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.
medium · analyst_question
Sunpharma Ltd — Q3 FY25
Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
FDA Compliance at Halol Facility
Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
high · management_commentaryLeqselvi Litigation Risk
If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.
high · management_commentaryClinical Trial Delays Impacting R&D Pipeline
Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
medium · analyst_question